Percutaneous Coronary Intervention
Conditions
Keywords
PCI, percutaneous coronary intervention
Brief summary
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidogrel or to one of three dose levels of PRT060128.
Detailed description
Each patient randomized in this trial will participate for approximately 12-24 weeks, including a Screening period of up to 2 weeks, the acute peri-procedural phase, and a 60-120 day chronic treatment phase. The chronic phase includes daily in-hospital assessments until 24 Hours or Discharge (whichever comes first), a telephone follow-up on Day 7-10 post-Discharge, outpatient follow-up visits on Days 30 and 60-67, \[Day 90 and Day 120 (if treated for 120 days)\] and a telephone follow-up 7 days following the last dose of study drug.
Interventions
DRUGclopidogrel
Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
DRUGPRT060128
80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
Sponsors
Portola Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The patient is scheduled to undergo non-urgent PCI * The patient is between 18 and 75 years of age (inclusive) and willing to comply with the protocol * Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours of dosing. All patients must agree to use double barrier contraception during the study and for at least 4 weeks after their last dose. * The patient or legally acceptable representative is able to read and give written informed consent and has signed an informed consent form approved by the Investigator's IRB/IEC
Exclusion criteria
* Estimated or measured weight \< 55 kg * Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI) within 7 days prior to PCI * Chronic total occlusion or unprotected left main stenting * Cardiogenic shock (systolic blood pressure \< 90 mm Hg requiring vasopressor or hemodynamic support) * Uncontrolled hypertension at the time of initial study drug administration defined as measured systolic blood pressure \> 190 mm Hg or diastolic blood pressure \> 108 mm Hg * Planned staged PCI * Planned surgery during the study period * Planned GP IIb/IIIa use * Patient has received a clopidogrel loading dose (≥300 mg) within 7 days prior to randomization; patients on maintenance clopidogrel may be enrolled * The planned administration of the study-specified clopidogrel loading dose is \>12 hours prior to PCI * Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g., warfarin) within the 7 days prior to PCI * Estimated creatinine clearance (e.g. Cockcroft-Gault) \< 45 mL/min * Anemia with hemoglobin level \< 10 g/dL * Thrombocytopenia (platelet count \< 100,000/mm3) * ALT and/or AST \> 2.5 x the ULN or other indication of clinically significant hepatic dysfunction * Facial or head trauma within the last 30 days * Intraocular hemorrhage within the last 30 days * Gastrointestinal bleeding within the last 30 days * Active bleeding, or history of a bleeding disorder or known intracranial vascular malformation * History of any prior ischemic stroke or TIA within the last 5 years or intracranial hemorrhage, neoplasm, or arteriovenous malformation * Known allergy or contraindication to the components of PRT060128, aspirin, heparin, clopidogrel, glycoprotein IIb/IIIa inhibitors, or to any contrast media * Participation in any investigational drug study within 30 days prior to enrollment. Participation in a device trial prior to enrollment is acceptable * Prior participation in any study involving PRT060128 * Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the patient's risk by participating in the study. This would include, but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy or any unexplained blackouts
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study is not powered to examine a pre-specified endpoint; rather it is designed to explore a number of analyses to understand the clinical efficacy, biological activity, and tolerability and safety of PRT060128 in patients undergoing non-urgent PCI | 24 Hours/Discharge and Day 60 |
Countries
Austria, Canada, Germany, Poland, United States
Outcome results
None listed